Continuous electronic fetal heart rate monitoring (EFM) is used in all but 9 of 250 maternity hospitals in the UK (Kelly T, RCOG survey). The technology became available commercially in the 1960s. Previously the fetal heart rate had been measured by intermittent auscultation between contractions. Initially there were high expectations that continuous monitoring would allow early recognition of hypoxia, with consequent timely intervention and avoidance of death or brain damage in the newborn. However, in the mid-1990s a Cochrane review of evidence from randomized control trials (RCTs) concluded that the only bene®t from EFM was a reduction in neonatal seizures 1 . Unless EFM was used in conjunction with fetal blood sampling it was associated with an increase in caesarean section rates. There was no reduction in perinatal mortality.
Paradoxically, the fourth report of Con®dential Enquiries into Stillbirths and Deaths in Infancy (CESDI) concludes that the major correctable error for avoidance of intrapartum related deaths was the interpretation of EFM traces. Since more than half such deaths were judged from the anonymized case notes to have been avoidable, the report indicates that EFM does have a part to play in avoidance of deaths 2 . Here I review the relative strengths and weaknesses of trial, meta-analysis of trials, observational and enquiry evidence, and discuss whether this con¯ict can be resolved.
TRIAL EVIDENCE
The ®rst two RCTs of continuous electronic fetal heart monitoring versus intermittent auscultation were published in 1976 3, 4 . Neither found an improvement in newborn outcome with continuous monitoring but both demonstrated an approximately twofold increase in caesarean delivery. By 1994 at least 12 RCTs had been published with a total of 58 855 labours. All showed higher caesarean section rates with EFM and in half this was statistically signi®cant. There was no reduction in perinatal deaths but one trial found a reduction in perinatal deaths due to fetal hypoxia 6 .
Most of the trials were small, ranging from 250 to 950. The two largest were the Dublin trial 7 involving just under 13 000 cases, and the Athens trial 6 with nearly 1500. But the weakness of all RCTs was the lack of statistical power to detect differences in rare outcomes, in particular perinatal death due to fetal hypoxia. In the UK in the 1990s, one such death occurred in 1500 deliveries 2 ; a trial size of 85 000 would be required to demonstrate a halving from 2 in 1500 to 1 in 1500. All trials recorded perinatal deaths as an outcome but most of the deaths in this category are from causes other than hypoxia in labour. Neonatal seizures occur in 2 per 1000 deliveries 8 . The Dublin trial 7 , the only RCT of adequate power, showed a signi®cant reduction in this outcome.
The effect of continuous EFM on more frequent outcomes such as caesarean section or instrumental delivery is easier to demonstrate. An increase in both interventions was observed: caesarean section rates increased in all trials; instrumental delivery increased in all but two trials.
In summary, the trials show a consistent increase in operative delivery with the use of EFM but all trials were too small to address the bene®t or otherwise of the technology in terms of rare serious outcomes for the baby, such as death or cerebral palsy.
META-ANALYSIS
Systematic reviews are crucial to public health policymaking. Meta-analysis, in which the data from individual trials are combined, increases the power to assess rare outcomes. By the mid-1990s 12 RCTs, and 2 systematic reviews 1,5 comprising 9 RCTs and 18561 labours, had been published. This is still well short of the 85000 needed to address death from perinatal asphyxia. Even if a metaanalysis could achieve adequate power it would still have the drawback of combining studies from substantially different clinical settings. The wide variation in outcome measures is illustrated by caesarean section rates in thè intermittent-auscultation' arms of the trials which ranged from 2% to 15.3% and perinatal deaths which ranged from 1 to 35 9 .
The size of the individual studies weights the metaanalysis. The Dublin study 7 dominates all systematic reviews, being ten times larger than the next largest study and up to thirty times the size of other studies. This trial dealt with low-risk labours, half the women delivering within two hours of admission to the labour ward; the caesarean section rate was 2.4% in the EFM group and 2.2% in the intermittent-auscultation group. The heterogeneity of the RCTs dilutes the effects observed in high-risk populations; for example, the Athens study 6 (the second largest) involved high-risk women and the EFM group showed a 60% reduction in perinatal deaths from hypoxia.
Conclusions may depend on which trials reviewers choose to include or exclude 10 . One meta-analysis showed a signi®cant reduction in perinatal deaths due to fetal hypoxia 9 whereas another 1 did not: the reason lay in inclusion or exclusion of a single large trial 6 .
Not all trials identi®ed intrapartum hypoxia deaths at the time of publication, and subsequent subanalysis on this is subject to variation in interpretation; thus, with cumulative meta-analysis of the existing trials we can expect continued debate on the merits or otherwise of EFM.
OBSERVATIONAL EVIDENCE
Randomized control trials are usually the best way to evaluate an intervention. However, when the outcome is rare then trials of appropriate size are likely to be impracticable. Despite their inherent biases, observational studies must contribute to any review of the evidence. Examination of historical trends might be of value.
In England and Wales, perinatal mortality fell from 21 per 1000 total births in 1973 to 8.2 per 1000 in 1998 11 . This was the period after introduction of EFM, but there are many confounding factors. Intrapartum death rates were not routinely collected until 1986, when death certi®cates were amended to indicate whether the stillbirth occurred before or during labour. In the years before this change, mortality coded as`anoxia of unspeci®ed cause' had been stable at 2 per 1000 in England and Wales until 1973, when there was a decline, again coinciding with the introduction of EFM. Since 1986 the Of®ce for National Statistics (ONS) has reported a category termed`intrapartum stillbirths with associated cause'. This accounts for 10% of all stillbirths and seems to be falling slightly 12 .
A review by Hornbuckle et al. 13 cites 13 observational studies comparing monitored with unmonitored pregnancies, and in 12 of them intrapartum deaths declined with the introduction of monitoring. However, before-and-after studies of this type are subject to secular trends. Furthermore, there may be a trend to publication bias. Only one of these studies adjusted for background risk: probably the women being monitored are a higher risk group, so the effect on mortality could be an underestimate. There have been two case±control studies 14, 15 demonstrating a signi®cant relationship between suboptimal intra-partum care and fetal death during labour, but both are subject to confounding factorsÐnamely antenatal risk, the use of continuous EFM and`presumed' intrapartum distress.
ENQUIRY EVIDENCE
The Con®dential Enquiry into Stillbirths and Deaths in Infancy (CESDI) dates from 1992. Its remit is to examine the causes of stillbirths, neonatal deaths and infant deaths and in particular to identify aspects of care that might have contributed to the unsatisfactory outcome. These functions are served by 16 regional coordinators (a clinically integrated network covering England, Wales and Northern Ireland) and a central secretariat.
CESDI is noti®ed of 99% of all deaths occurring between 20 weeks' gestation and 1 year of life, approximately 10 000 deaths annually. A subset of these is chosen for enquiry. Clinicians enter the cause of death on the noti®cation form after a review of the clinical and pathological ®ndings. A case-by-case ascertainment check with the Of®ce for National Statistics ensures identi®cation of all relevant deaths. The ®rst enquiry topic was deaths of normally formed babies weighing above 1.5 kg due to an event in labour, 1993±1996; the ®ndings were published in 1997 2 .
The enquiries are held on a regional basis by a multidisciplinary panel which reviews the anonymized case records. Panel members are from within the region but are not from the unit associated with the case. There is no direct feedback to the units or individuals involved and the results are summarized regionally and nationally to form the basis of the annual report.
The ®ndings suggest that over half the intrapartumrelated deaths are avoidable. Panels were asked to comment on areas of suboptimal care in the antenatal, intrapartum or postpartum period. Of the 1708 comments made on intrapartum care the commonest area of concern related to the interpretation of fetal heart traces (791 comments) 2 . The robustness of the panel assessments in 1995 was assessed in a second-pass panel exercise 16 and the topic most likely to be identi®ed consistently by both panels was dif®culty in interpreting EFM. However, the unstructured approach used in 1995 led to the recommendation of providing prede®ned standards for guidance at a panel enquiry 16 . These ®ndings related to deaths alone; they did not include observations in women with normal outcomes, and the remit of the panels was to identify suboptimal care. Probably, therefore, the enquiries overemphasized the importance of obstetric care in causing death.
RESOLVING THE CONFLICT
Future studies, be they trial, observational or enquiry, need to address the lack of standardization in interpretation of the FHR pattern 17 . Interobserver and intraobserver reliability is low 18, 19 . One-third of labours have some form of variant, and Meta-analysis will always suffer the disadvantage of joining studies which differ substantially in their setting and entry criteria. Retrospective subdivision of perinatal deaths due to hypoxia is subjective and small changes in these numbers are highly in¯uential in the interpretation of the meta-analysis. Many of the past studies are not representative of current practice and meta-analysis will not provide an agreed and de®nitive answer.
The ideal remains the RCT, but can we realistically expect a randomized trial involving 85 000 labours, comparing continuous fetal heart monitoring with intermittent auscultation? This number represents just over one-eighth of all deliveries in the UK annually. If the question is restricted to low-risk women and if we assume two-thirds of all pregnancies are in this category, then at least one in ®ve of all suitable maternities would need to be recruited to achieve adequate numbers in a year and this takes no account of the individual preferences of health professionals and mothers. Strongly held opinions in either direction are likely to result in non-participation. Even if the issues of numbers and preference could be dealt with, we would have to address the practicalities of the one-to-one midwifery required for intermittent auscultation; unfortunately, human companions are more resource-intensive than their electronic equivalents. Thus a trial of adequate size seems unlikely. This leaves observational and enquiry studiesÐthe case±control approach where the intrapartum care in deaths is compared with that in well babies. In case±control studies the choice of appropriate controls is particularly problematic. The major confounding factors are antenatal risk factors and intrapartum fetal distress. Probably, more complex decisions will be necessary in the cases than the controls. Agreed criteria are needed for management of suboptimal traces and there is the additional dif®culty of assessing care in the intermittentauscultation group where a continuous record will not exist (so presumed fetal distress is less likely to occur). Ultimately the ®ndings of the case±control approach can only be supportive or otherwise, not de®nitive.
With the founding of the National Institute for Clinical Excellence, central guidance on participation in trials becomes a possibility. Some people may argue that the possible risks and bene®ts of EFM technology need clear answers. But if the evidence went against EFM, would the technology then be removed? Before this could happen there would need to be widespread debate, including not just health professionals but mothers as well. Meanwhile, this is a key area for the National Institute for Clinical Excellence. The con¯ict between the enquiries and the trial evidence is destined to continue rather than be resolved.
